Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 8/2014

01-08-2014 | Original paper

Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data

Authors: Jill K. Schinkel, Shelia Hoar Zahm, Ismail Jatoi, Katherine A. McGlynn, Christopher Gallagher, Catherine Schairer, Craig D. Shriver, Kangmin Zhu

Published in: Cancer Causes & Control | Issue 8/2014

Login to get access

Abstract

Background

Compared to non-inflammatory breast cancer (non-IBC), inflammatory breast cancer (IBC) has less favorable survival and is more likely to be estrogen receptor (ER) and progesterone receptor (PR) negative. ER−/PR− tumors, regardless of histology, have less favorable survival. While black women are more likely to have IBC and ER−/PR− tumors than white women, it is unclear whether the racial disparity in survival is explained by these factors. The objective of this study was to assess racial/ethnic differences in breast cancer survival by inflammatory status and hormone receptor status.

Methods

This study examined breast cancer mortality among non-Hispanic white (NHW), Hispanic white, black, and Asian/Pacific Islander (API) women diagnosed between 1990 and 2004 using the National Cancer Institute’s Surveillance, Epidemiology, and End Results data. Kaplan–Meier survival curves and Cox proportional hazard ratios (HRs) assessed the relationship between race/ethnicity and survival.

Results

Black women had significantly poorer survival than NHW women regardless of inflammatory status and hormone receptor status. Compared to NHWs, the HRs for black women were 1.32 (95 % confidence interval (CI) 1.21–1.44), 1.43 (95 % CI 1.20–1.69), and 1.30 (95 % CI 1.16–1.47) for IBC, IBC with ER+/PR+, and with ER−/PR−, respectively. Similar HRs were found for non-IBC, non-IBC with ER+/PR−, and non-IBC with ER−/PR−. API women had significantly better survival than NHW women regardless of inflammatory status and hormone receptor status.

Conclusion

Compared to NHW women, black women had poorer survival regardless of inflammatory status and hormone receptor status and API women had better survival. These results suggest that factors other than inflammatory status and hormone receptor status may play a role in racial/ethnic disparities in breast cancer survival.
Literature
1.
Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2013) SEER Cancer Statistics Review, 1975–2010. National Cancer Institute, Bethesda, MD
2.
Dawood S, Ueno NT, Valero V et al (2011) Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 117:1819–1826PubMedCrossRef
3.
Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Inst 97:966–975PubMedCentralPubMedCrossRef
4.
Yang R, Cheung MC, Hurley J et al (2009) A comprehensive evaluation of outcomes for inflammatory breast cancer. Breast Cancer Res Treat 117:631–641PubMedCrossRef
5.
Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI (2005) Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 103:2241–2251PubMedCrossRef
6.
Knight WA, Livingston RB, Gregory EJ, McGuire WL (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669–4671PubMed
7.
Ravdin PM, Green S, Dorr TM et al (1992) Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10:1284–1291PubMed
8.
Shek LL, Godolphin W, Spinelli JJ (1987) Oestrogen receptors, nodes and stage as predictors of post-recurrence survival in 457 breast cancer patients. Br J Cancer 56:825–829PubMedCentralPubMedCrossRef
9.
Klintenberg C, Stal O, Nordenskjold B, Wallgren A, Arvidsson S, Skoog L (1986) Proliferative index, cytosol estrogen receptor and axillary node status as prognostic predictors in human mammary carcinoma. Breast Cancer Res Treat 7(Suppl):S99–S106PubMed
10.
Joslyn SA (2002) Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat 73:45–59PubMedCrossRef
11.
Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6PubMedCentralPubMedCrossRef
12.
Elledge RM, Clark GM, Chamness GC, Osborne CK (1994) Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86:705–712PubMedCrossRef
13.
14.
Zell JA, Tsang WY, Taylor TH, Mehta RS, Anton-Culver H (2009) Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res 11:R9PubMedCentralPubMedCrossRef
15.
Overview of the SEER Program: Surveillance, Epidemiology, and End Results Program
16.
Shama R, Hamilton A, Beith J (2008) LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev 4:CD004562
17.
18.
19.
20.
Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) American joint committee on cancer, cancer staging manual, 7th ed. Springer, New York
21.
Schlichting JA, Soliman AS, Schairer C, Schottenfeld D, Merajver SD (2012) Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990–2008. Breast Cancer Res Treat 134:1257–1268PubMedCrossRef
22.
23.
Kwan ML, Sweeney C, Habel LA, Weltzien E, Castillo A, Davis C, Factor RE, Kroenke CH, Shakespear K, Quesenberry CP, Stijleman IJ, Bernard PS, Kushi LH, Caan BJ (2013) Hormonal risk factors and breast cancer prognosis and survival by PAM50 molecular subtype. Poster presented at: American Association for Cancer Research Annual Meeting. Walter E, Washington Convention Center, Washington DC
24.
Ma H, Lu Y, Malone KE et al (2013) Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. BMC Cancer 13:225PubMedCentralPubMedCrossRef
25.
2012 National Healthcare Disparities Report: Agency for Healthcare Research and Quality
26.
Elmore JG, Nakano CY, Linden HM, Reisch LM, Ayanian JZ, Larson EB (2005) Racial inequities in the timing of breast cancer detection, diagnosis, and initiation of treatment. Med Care 43:141–148PubMedCrossRef
27.
Hoffman HJ, LaVerda NL, Levine PH, Young HA, Alexander LM, Patierno SR (2011) Having health insurance does not eliminate race/ethnicity-associated delays in breast cancer diagnosis in the District of Columbia. Cancer 117:3824–3832PubMedCrossRef
28.
Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ (2006) Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol 24:85–94PubMedCrossRef
29.
Lund MJ, Brawley OP, Ward KC, Young JL, Gabram SS, Eley JW (2008) Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat 109:545–557PubMedCrossRef
30.
Barcenas CH, Wells J, Chong D, French J, Looney SW, Samuel TA (2010) Race as an independent risk factor for breast cancer survival: breast cancer outcomes from the medical college of Georgia tumor registry. Clin Breast Cancer 10:59–63PubMedCrossRef
31.
Du W, Simon MS (2005) Racial disparities in treatment and survival of women with stage I–III breast cancer at a large academic medical center in metropolitan Detroit. Breast Cancer Res Treat 91:243–248PubMedCrossRef
32.
Worthington J, Waterbor JW, Funkhouser E, Falkson C, Cofield S, Fouad M (2008) Receipt of standard breast cancer treatment by African American and White women. Int J Med Sci 5:181–188PubMedCentralPubMedCrossRef
33.
Fedewa SA, Ward EM, Stewart AK, Edge SB (2010) Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004–2006. J Clin Oncol 28:4135–4141PubMedCrossRef
34.
Tammemagi CM (2007) Racial/ethnic disparities in breast and gynecologic cancer treatment and outcomes. Curr Opin Obstet Gynecol 19:31–36PubMedCrossRef
35.
Bhargava A, Du XL (2009) Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer 115:2999–3008PubMedCrossRef
36.
Keating NL, Kouri E, He Y, Weeks JC, Winer EP (2009) Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery? Med Care 47:765–773PubMedCrossRef
37.
Markossian TW, Hines RB (2012) Disparities in late stage diagnosis, treatment, and breast cancer-related death by race, age, and rural residence among women in Georgia. Women Health 52:317–335PubMedCrossRef
38.
Short LJ, Fisher MD, Wahl PM et al (2010) Disparities in medical care among commercially insured patients with newly diagnosed breast cancer: opportunities for intervention. Cancer 116:193–202PubMed
39.
Bickell NA, Wang JJ, Oluwole S et al (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24:1357–1362PubMedCrossRef
40.
41.
Martinez SR, Beal SH, Chen SL et al (2010) Disparities in the use of radiation therapy in patients with local-regionally advanced breast cancer. Int J Radiat Oncol Biol Phys 78:787–792PubMedCentralPubMedCrossRef
42.
Chu KC, Lamar CA, Freeman HP (2003) Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer 97:2853–2860PubMedCrossRef
43.
Lund MJ, Trivers KF, Porter PL et al (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113:357–370PubMedCrossRef
44.
Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRef
45.
46.
Dookeran KA, Dignam JJ, Holloway N et al (2012) Race and the prognostic influence of p53 in women with breast cancer. Ann Surg Oncol 19:2334–2344PubMedCrossRef
47.
Sachdev JC, Ahmed S, Mirza MM, Farooq A, Kronish L, Jahanzeb M (2010) Does race affect outcomes in triple negative breast cancer? Breast Cancer (Auckl) 4:23–33
48.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728PubMedCrossRef
49.
Sparano JA, Wang M, Zhao F et al (2012) Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 104:406–414PubMedCentralPubMedCrossRef
50.
Dawood S, Broglio K, Kau SW et al (2009) Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27:220–226PubMedCrossRef
51.
Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX (2013) Racial differences in outcomes of triple-negative breast cancer. Breast Cancer Res Treat 138:281–289PubMedCrossRef
52.
Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA (2010) Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 102:1584–1598PubMedCentralPubMedCrossRef
53.
Li CI, Malone KE, Daling JR (2003) Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 163:49–56PubMedCrossRef
54.
Crew KD, Capodice JL, Greenlee H et al (2010) Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 28:1154–1160PubMedCrossRef
55.
Kapp JM, Walker R, Haneuse S, Yankaskas BC (2011) A prospective assessment of racial/ethnic differences in future mammography behavior among women who had early mammography. Cancer Epidemiol Biomark Prev 20:600–608CrossRef
56.
Daroui P, Gabel M, Khan AJ, Haffty BG, Goyal S (2012) Utilization of breast conserving therapy in stages 0, I, and II breast cancer patients in New Jersey: an American College of Surgeons National Cancer Data Base (NCDB) analysis. Am J Clin Oncol 35:130–135PubMedCrossRef
57.
Gelber RP, McCarthy EP, Davis JW, Seto TB (2006) Ethnic disparities in breast cancer management among Asian Americans and Pacific Islanders. Ann Surg Oncol 13:977–984PubMedCrossRef
58.
Tannenbaum SL, Koru-Sengul T, Miao F, Byrne MM (2013) Disparities in survival after female breast cancer diagnosis: a population-based study. Cancer Causes Control 24:1705–1715PubMedCrossRef
Metadata
Title
Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data
Authors
Jill K. Schinkel
Shelia Hoar Zahm
Ismail Jatoi
Katherine A. McGlynn
Christopher Gallagher
Catherine Schairer
Craig D. Shriver
Kangmin Zhu
Publication date
01-08-2014
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 8/2014
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-014-0395-1

Other articles of this Issue 8/2014

Cancer Causes & Control 8/2014 Go to the issue

Original paper

Validity of a self-administered food frequency questionnaire in the estimation of heterocyclic aromatic amines

Original paper

HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in the southeastern USA

Brief report

Serum uric acid levels and cancer mortality risk among males in a large general population-based cohort study

Erratum

Erratum to: Childhood acute leukemia, maternal beverage intake during pregnancy, and metabolic polymorphisms

Original paper

Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage

Original paper

To what extent is women’s economic situation associated with cancer screening uptake when nationwide screening exists? A study of breast and cervical cancer screening in France in 2010
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits